TFF Pharmaceuticals
The business, the turning points, and the decisions behind them.
01 / WHAT IT BUILT
What the company did
TFF Pharmaceuticals (Nasdaq: TFFP) was a clinical-stage biopharmaceutical company based in Fort Worth, Texas, incorporated in January 2018. It developed inhaled dry-powder drugs based on its patented Thin Film Freezing (TFF) platform, licensed exclusively from the University of Texas at Austin, aiming to improve the bioavailability of poorly water-soluble drugs for pulmonary diseases. It raised about $72.9 million across equity offerings.
02 / TFF Pharmaceuticals FAILURE REASONS
Failure reasons
TFF ran out of runway: by September 2024 it held $1.3 million in cash against a $2.4 million working-capital deficit, and small dilutive raises ($1.2M and $4.2M) bought little time. After a strategic review found no viable alternative, the board approved complete dissolution and liquidation on November 14, 2024, terminating nearly all employees and the UT Austin patent license.
03 / EVENT HISTORY
Events in the structured record
- Incorporated and licensed
TFF Pharmaceuticals is incorporated in Delaware on January 24, 2018, and builds its pipeline on thin-film-freezing patents licensed from UT Austin.
- Final raises, then dissolution
TFF raises $1.2M in March and $4.2M in May 2024; on November 14 the board approves complete liquidation and dissolution, terminates substantially all employees, and appoints wind-down specialist Craig Jalbert as sole CEO.
04 / CONTEMPORARY REBUILD ASSESSMENT
Difficulty of rebuilding this project today
Material for this section is being gathered and checked. It will appear here once ready.
Overall assessment: Not completed
05 / CAUSAL CHAIN
How the factors connect
- 01
On November 14, 2024, TFF announced it had terminated its employees and would wind down operations.
- 02
The board approved a plan of complete liquidation and dissolution, subject to stockholder approval.
- 03
The company expected no amounts would be available for distribution to shareholders.